Elevance Health reported third-quarter 2026 operating revenue of $50.4 billion, a 0.7% increase from the prior year, driven by higher premium yields and growth in CarelonRx product revenue. Diluted earnings per share reached $6.27, while adjusted diluted EPS was $6.99. The company raised its full-year 2026 guidance, increasing adjusted diluted EPS to at least $29.00 and operating cash flow to at least $6.5 billion. Additionally, Elevance Health declared a fourth-quarter dividend of $1.72 per share, payable on December 18, 2026, to shareholders of record as of December 4, 2026. The company operates in the health insurance and healthcare services industry.
